Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
1998-06-04
2001-10-09
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C424S151100, C424S805000, C424S810000, C514S021800, C530S388220, C530S388600, C530S862000, C530S866000
Reexamination Certificate
active
06299875
ABSTRACT:
BACKGROUND OF THE INVENTION
The symptoms of allergy in humans and animals are primarily attributable to the release of histamine and a large variety of other bioactive compounds from mast cells and related cell types. The mast cell contains numerous secretary granules in which these substances are stored at extremely high concentrations. Activation of the mast cell results in the fusion of these granules with the cell surface membrane, leading to the exocytosis of the granule contents and the concomitant induction of allergic symptoms. The plasma membrane of these cells are endowed with receptors for the Fc portion of the IgE (Fc&egr;RI). This receptor binds circulating IgE with very high affinity and retains it at the mast cell surface for extended periods of time. Activation is accomplished through the binding of an allergen simultaneously to more than one polyvalent molecule of Fc&egr;RI-bound IgE. This “cross linking” of at least two surface-bound IgE molecules brings Fc&egr;RI proteins into close association with one another in the plane of the mast cell plasma membrane. Kinases associated with these receptors become activated as a result of this proximity, initiating the second messenger cascade which results in cell degranulation.
At least one other class of receptors can bind to the Fc portion of IgE. The low affinity receptor for IgE, Fc&egr;RII (also known as CD23) is expressed on mast cells and related cell types, B cells, and subsets of antigen presenting cells. It has been suggested that occupancy of Fc&egr;RII negatively regulates IgE synthesis.
It is an object of the present invention to provide a means and method of preventing activation and degranulation of mast cells and related cell types in response to exposure to allergens.
SUMMARY OF THE INVENTION
Compositions are administered to block IgE binding to cell surface receptors and ultimately displace native IgE from mast cells and related cell types to prevent the activation of these cells during an allergic response and to reduce native IgE synthesis. The compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc&egr;RI IgE binding sites, and more preferably, Fc&egr;RI and Fc&egr;RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens. The compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the IgE, jointly referred to herein as “IgE fragments” unless otherwise stated.
REFERENCES:
patent: 3625214 (1971-12-01), Higuchi et al.
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4789734 (1988-12-01), Ruoslahti et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5612895 (1997-03-01), Balaji et al.
patent: 5770396 (1998-06-01), Kinet
patent: 0 499 112 A1 (1992-08-01), None
patent: WO 93/04173 A1 (1993-03-01), None
patent: WO 95/14779 A1 (1995-06-01), None
patent: WO 96/12741 A1 (1996-05-01), None
patent: WO 97/04807 A1 (1997-03-01), None
Kitani, S, et al., Inhibition of allergic reactions with monoclonal antibody to the high affinity IgE receptor. J. Immunol. 140(8):2585-2588, Apr. 15, 1988.*
Allen, F. H., et al., “The Cambridge Crystallographic Data Centre: Computer-Based Search, Retrieval, Analysis and Display of Information,”Acta Crystallogr., B35: 2331-2339, (1979).
Baniyash, et al. “Anti-IgE Monoclonal Antibodies Directed at the Fc, Receptor Binding Site,”Molec. Immunol. 25:705-711, (1988).
Bonini, et al. “HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogenic Graft-Versus-Leukemia,”Science276: 1719-1724, (1997).
Brent, et al., “Upperbound Procedures for the Identification of Similar Three-Dimensional Chemical Structures,”J. Comput.-Aided Mol. Design, 2: 311-310, (1988).
Burt, et al., “Analysis of the Interaction Between Rat Immunoglobulin E and Rat Mast Cells Using Anti-Peptide Antibodies,”Molec. Immunol. 24: 379-389, (1987).
Clackson, T., et al., “Making Antibody Fragments Using Phage Display Libraries,”Nature, 352:624-688, (1991).
Coleman, et al., “Inhibition of Mast Cell Sensitization in vitro by a Human Immunoglobulin ,-chain Fragment Synthesized inEscherichia coli*,” Eur. J. Immunol. 15:966-969, (1985).
Cooper, et al., “A Novel Approach to Molecular Similarity,”J. Comput.-Aided Mol. Design, 3: 253-259 (1989) and references cited therein.
Daugherty, et al., “Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins,”Nucl. Acids Res., 19:2471-2476 (1991).
Durham, et al., “Expression of , Germ-Line Gene Transcripts and mRNA for the , Heavy Chain of IgE in Nasal B Cells and the Effects of Topical Corticosteriod,”Eur. J. Immunol. 27: 2899-2906, (1997).
Durham, et al., “Local IgE Production in Nasal Allergy,”Int. Arch. of Allergy and Immunol. 113: 128-130, (1997).
Ellington & Szostak, “In Vitro Selection of RNA Molecules that Bind Specific Ligands,”Nature346:818-822, (1990).
Ellington & Szostak, “Selection in vitro of Single-Stranded DNA Molecules that Fold into Specific Ligand-Binding Structures,”Nature355:850-852, Feb., (1992).
Elliot, et al., “Parenteral Absorption of Insulin from the Lung in Diabetic Children,”Aust. Paediatr. J. 23: 293-297, (1987).
Geha, et al., “Inhibition of the Prausnitz-K&eegr;stner Reaction by an Immunoglobulin ,-Chain Fragment Synthesized inE. coli,” Nature. 315:577-578, (1985).
Bensch, et al., “Absorption of Intact Protein Molecules across the Pulmonary Air-Tissue Barrier,”Science157:1204-10206, (1967).
Ghoshal et al., “Computer Aids in Drug Design—Highlights”Pol. J. Pharmacol. 48(4), 359-377, (1996).
Helm, et al., “Identification of the High Affinity Receptor Binding Region in Human Immunoglobulin E*,”J. Biol. Chem. 271: 7494-7500, (1996).
Helm, et al., “The Mast Cell Binding Site on Human Immunoglobulin E,”Nature331: 180-183, (1988).
Helm, et al., “Blocking of Passive Sensitization of Human Mast Cells and Basophil Granulocytes with IgE Antibodies by a Recombinant Human ,-Chain Fragment of 76 Amino Acids,”Proc. Nat. Acad. Sci. 86:9465-9469, (1989).
Huang et al., “Development of a Common 3D Pharmacophore for Delta-Opioid Recognition From Peptides and Non-Peptides Using a Novel Computer program”J. Comput. Aided Mol. Des. 11(1): 21-78, (1997).
Ikeyama, “Purification and Characterization of Recombinant Human IgE Fc, Fragment Produced in Mouse L Cells,” Molec. Immunol. 24: 1039-1046, (1987).
Isersky, et al., “The Fate of IgE Bound to Rat Basophilic Leukemia Cells,”J. Immunol. 122: 1926-1936, (1979).
Ishizaka, et al., “Biological Properties of a Recombinant Human Immunoglobulin ,-Chain Fragment,”Proc. Nat. Acad. Sci. 83:8323-8327, (1986).
Kamiya, “Unsusceptibility of Recombinant Human Fc Fragments of Immunoglobulin E to Thrombin,”Human Antibodies and Hybridomas7:42-47, (1996).
Keegan, et al., “Characterization of New Rat Anti-Mouse IgE Monoclonals and Their Use Along With Chimeric IgE to Further Define the Site that Interacts with Fc,RII and Fc,RI,”Molec. Immunol. 28: 1149-1154, (1991).
Kenten, et al., “Properties of a Human Immunoglobulin Chain Fragment Synthesized inEscherichia coli,” Proc. Nat. Acad. Sci. 81:2955-2959, (1984).
Keown, et al., “Basis of the 1:1 Stoichiometry of the High Affinity Receptor Fc,RI-IgE Complex,”Eur. Biophys J. 25: 471-476, (1997).
Kleinberg and Wanke, “New Approaches and Technologies in Drug Design and Discovery,”Am. J. Health Syst. Pharm. 52(12): 1323-1336, (1995).
Kubinyi, “Strategies and Recent Technologies in Drug Discovery”Pharmazie50(10): 647-662, (1995).
Kurokawa, et al., “Expression of Human Immunoglobulin E Chai
Caplan Michael
Sosin Howard
Choate Hall & Stewart
Herschbach Jarrell Brenda
Panacea Pharmaceuticals, LLC
Saunders David
Tung Mary Beth
LandOfFree
Methods to block IGE binding to cell surface receptors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to block IGE binding to cell surface receptors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to block IGE binding to cell surface receptors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2585167